Jie Meng,1 Johanna Lister,1 Anne-Lise Vataire,2 Roman Casciano,1 Jerome Dinet2 1Analytica Laser, London, UK; 2Ipsen Pharma, Boulogne-Billancourt, France Purpose: The aim of this study was to compare the cost-effectiveness of cabozantinib with the standard of care in England in adult patients with advanced renal cell carcinoma (aRCC), following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy. Methods: We developed a partitioned-survival model with three health states to assess the cost-effectiveness of cabozantinib and its comparators. The model time horizon was 30 years. Efficacy and safety data were derived from pivotal clinical trials (METEOR: NCT01865747, CheckMate025: NCT01668784, and AXIS: NCT00678392). ...
ObjectiveAdvanced renal cell carcinoma (RCC) is commonly treated with vascular endothelial growth fa...
Background: New targeted therapeutics for metastatic renal cell carcinoma (mRCC) enable an increment...
Background: New targeted therapeutics for metastatic renal cell carcinoma (mRCC) enable an increment...
Background. Currently there exists a wide range of advanced renal cell carcinoma (RCC) treatment sch...
Introducción: El carcinoma de células renales (CCR) es la segunda neoplasia urogenital en frecuencia...
Background: Several therapies have recently been approved for use in the NHS for pretreated advanced...
Introduction: Renal cell carcinoma (RCC) is the most common form of kidney cancer with >30% already ...
Introduction: Clear cell Renal Cell Carcinoma (RCC), par- ticularly when diagnosed at an advanced st...
Introduction: Clear cell Renal Cell Carcinoma (RCC), par- ticularly when diagnosed at an advanced st...
BackgroundIn the Checkmate9ER trial, first-line treatment with nivolumab combined with cabozantinib ...
Introduction: Clear cell Renal Cell Carcinoma (RCC), par- ticularly when diagnosed at an advanced st...
Introduction: Clear cell Renal Cell Carcinoma (RCC), par- ticularly when diagnosed at an advanced st...
Abstract Background We evaluated the cost-effectiveness of nivolumab versus everolimus in patients w...
Master in Health Economics and Pharmaeconomics. (UPF Barcelona School of Management). Curs 2017-2020...
Abstract Background Nivolumab plus ipilimumab improves overall survival and is associated with less ...
ObjectiveAdvanced renal cell carcinoma (RCC) is commonly treated with vascular endothelial growth fa...
Background: New targeted therapeutics for metastatic renal cell carcinoma (mRCC) enable an increment...
Background: New targeted therapeutics for metastatic renal cell carcinoma (mRCC) enable an increment...
Background. Currently there exists a wide range of advanced renal cell carcinoma (RCC) treatment sch...
Introducción: El carcinoma de células renales (CCR) es la segunda neoplasia urogenital en frecuencia...
Background: Several therapies have recently been approved for use in the NHS for pretreated advanced...
Introduction: Renal cell carcinoma (RCC) is the most common form of kidney cancer with >30% already ...
Introduction: Clear cell Renal Cell Carcinoma (RCC), par- ticularly when diagnosed at an advanced st...
Introduction: Clear cell Renal Cell Carcinoma (RCC), par- ticularly when diagnosed at an advanced st...
BackgroundIn the Checkmate9ER trial, first-line treatment with nivolumab combined with cabozantinib ...
Introduction: Clear cell Renal Cell Carcinoma (RCC), par- ticularly when diagnosed at an advanced st...
Introduction: Clear cell Renal Cell Carcinoma (RCC), par- ticularly when diagnosed at an advanced st...
Abstract Background We evaluated the cost-effectiveness of nivolumab versus everolimus in patients w...
Master in Health Economics and Pharmaeconomics. (UPF Barcelona School of Management). Curs 2017-2020...
Abstract Background Nivolumab plus ipilimumab improves overall survival and is associated with less ...
ObjectiveAdvanced renal cell carcinoma (RCC) is commonly treated with vascular endothelial growth fa...
Background: New targeted therapeutics for metastatic renal cell carcinoma (mRCC) enable an increment...
Background: New targeted therapeutics for metastatic renal cell carcinoma (mRCC) enable an increment...